Status:
COMPLETED
COVID-19 Convalescent Plasma Therapy
Lead Sponsor:
Universidad Nacional de Asunción
Collaborating Sponsors:
Consejo Nacional de Ciencias y Tecnología, Paraguay
Ministerio de Salud Pública y Bienestar Social, Paraguay
Conditions:
SARS-CoV-2 Infection
COVID-19 Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
This study is an open-label trial in which hospitalized patients with risk factors of severe coronavirus disease 2019 \[COVID-19\] will be receive treatment with convalescent plasma (≤ 15 days from sy...
Eligibility Criteria
Inclusion
- 18 Years and older
- Presence of risk factors of severe COVID 19 diagnosed by quantitative polymerase chain reaction by reverse transcription (RT-qPCR)
- Patients with no more than 15 days from the onset of symptoms
- Signed informed consent
Exclusion
- Severely ill patients admitted directly to the ICU.
- Need for mechanical ventilation at the time of hospital admission, regardless of the time of clinical evolution.
- History of previous hypersensitivity to plasma transfusions.
- History of immunoglobulin A (IgA) deficiency
- Pregnancy
Key Trial Info
Start Date :
August 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 10 2021
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT04747158
Start Date
August 10 2020
End Date
January 10 2021
Last Update
March 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Facultad de Ciencias Médicas - Universidad Nacional de Asunción
Asunción, Paraguay, 111421